MA29215B1 - Pyrazolo[3,4-b] pyridines et indazoles therapeutiques - Google Patents

Pyrazolo[3,4-b] pyridines et indazoles therapeutiques

Info

Publication number
MA29215B1
MA29215B1 MA29948A MA29948A MA29215B1 MA 29215 B1 MA29215 B1 MA 29215B1 MA 29948 A MA29948 A MA 29948A MA 29948 A MA29948 A MA 29948A MA 29215 B1 MA29215 B1 MA 29215B1
Authority
MA
Morocco
Prior art keywords
indazoles
pyrazolo
pyridines
therapeutic
formula
Prior art date
Application number
MA29948A
Other languages
English (en)
Inventor
Robert M Schelkun
Po-Wai Yuen
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA29215B1 publication Critical patent/MA29215B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I), DANS LAQUELLE R2, R3, R4, R5, R6, R7, X, ET L REPRÉSENTENT UNE DES VALEURS DÉFINIES DANS LA SPÉCIFICATION, ET DES SELS ACCEPTABLES PHARMACEUTIQUEMENT ASSOCIÉS, QUI SONT UTILISÉS EN TANT QU'AGENTS DANS LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL ET D'AUTRES TROUBLES, Y COMPRIS, LE TROUBLE D'HYPERACTIVITÉ AVEC DÉFICIT DE L'ATTENTION, UNE DOULEUR NEUROPATHIQUE, L'INCONTINENCE URINAIRE, L'ANXIÉTÉ, LA DÉPRESSION, LA SCHIZOPHRÉNIE ET LA FIBROMYALGIE. CETTE INVENTION A AUSSI POUR OBJET DES COMPOSITIONS PHARMACEUTIQUES RENFERMANT AU MOINS UN COMPOSÉ DE LA FORMULE (I).
MA29948A 2004-11-29 2007-05-29 Pyrazolo[3,4-b] pyridines et indazoles therapeutiques MA29215B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63138604P 2004-11-29 2004-11-29

Publications (1)

Publication Number Publication Date
MA29215B1 true MA29215B1 (fr) 2008-02-01

Family

ID=36218221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29948A MA29215B1 (fr) 2004-11-29 2007-05-29 Pyrazolo[3,4-b] pyridines et indazoles therapeutiques

Country Status (29)

Country Link
US (3) US7423054B2 (fr)
EP (1) EP1828182B1 (fr)
JP (1) JP4130219B2 (fr)
KR (1) KR20070094747A (fr)
CN (1) CN101111494A (fr)
AP (1) AP2007004024A0 (fr)
AR (1) AR051970A1 (fr)
AT (1) ATE460415T1 (fr)
AU (1) AU2005308523B2 (fr)
BR (1) BRPI0518693A2 (fr)
CA (1) CA2588812A1 (fr)
CR (1) CR9155A (fr)
DE (1) DE602005019913D1 (fr)
DK (1) DK1828182T3 (fr)
EA (1) EA012245B1 (fr)
ES (1) ES2339794T3 (fr)
GT (1) GT200500348A (fr)
IL (1) IL183485A0 (fr)
MA (1) MA29215B1 (fr)
MX (1) MX2007006408A (fr)
NL (2) NL1030540C2 (fr)
NO (1) NO20072972L (fr)
PA (1) PA8653901A1 (fr)
PE (1) PE20061062A1 (fr)
TN (1) TNSN07207A1 (fr)
TW (1) TWI304063B (fr)
UY (1) UY29228A1 (fr)
WO (1) WO2006056873A2 (fr)
ZA (1) ZA200704408B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
KR20070094747A (ko) * 2004-11-29 2007-09-21 워너-램버트 캄파니 엘엘씨 치료용 피라졸로［３,４-ｂ］피리딘 및 인다졸
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2929883A1 (fr) * 2014-04-08 2015-10-14 Institut Pasteur Dérivés du pyrazole en tant qu'inhibiteurs de la dihydrooratate déhydrogénase (DHODH)
CN107082763A (zh) * 2016-02-15 2017-08-22 中山大学 一种合成吲唑酮类化合物的方法
UY39801A (es) * 2021-06-04 2022-12-30 Pi Industries Ltd Un proceso novedoso para la preparación de diamidas antranílicas

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428634A (en) 1965-03-13 1969-02-18 Acraf 3-tertiary amino alkoxy-1-hydrocarbon indazoles
US3488353A (en) 1967-05-29 1970-01-06 Sterling Drug Inc New 1-((2-azaindolyl)-lower-alkyl) 4-substituted-piperazines
US3712903A (en) 1968-04-17 1973-01-23 Cutter Lab 5(1-(phenyl or benzyl)-1h-indazol-3-yloxymethyl)-tetrazoles
IT1061791B (it) 1969-01-27 1983-04-30 Italfarmaco Spa Derivati indazolici ad attivita antiinfiammatoria e anagesica
US3681382A (en) 1969-02-07 1972-08-01 Ciba Geigy Corp 3-aminoindazoles
US3678059A (en) 1969-10-07 1972-07-18 Ciba Geigy Corp 3-aminoalkylidene-indazoles
IT1044784B (it) * 1970-12-15 1980-04-21 Italfarmaco Spa Farmaco adnattivita analgesica e antiinfiammatoria
DE3166987D1 (en) 1980-09-18 1984-12-06 Asahi Chemical Ind 3-aminoindazole derivatives and process for preparation thereof
JPS58159469A (ja) 1982-03-17 1983-09-21 Asahi Chem Ind Co Ltd 新規な１，３位ジ置換３−アミノインダゾ−ル誘導体およびその製造法
HU198036B (en) 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
US4710573A (en) 1983-08-22 1987-12-01 Hoechst Roussel Pharmaceuticals, Inc. 3-(piperidinyl)-and 3-(pyrrolidinyl)-1H-indazoles
US4758668A (en) 1983-08-22 1988-07-19 Hoechst-Roussel Pharmaceuticals Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4775761A (en) 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4670447A (en) 1983-08-22 1987-06-02 Hoechst-Roussel Pharmaceuticals Inc. Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4853470A (en) 1983-08-22 1989-08-01 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4806649A (en) 1983-08-22 1989-02-21 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3- (pyrrolidinyl)-1H-indazoles
US4933460A (en) 1983-08-22 1990-06-12 Hoechst-Roussel Pharmaceuticals Inc. Piperdine substituted phenyl hydrazones
DE3338903A1 (de) 1983-10-27 1985-05-09 Basf Ag, 6700 Ludwigshafen Neue 2-phenylindazole und deren verwendung
US5134236A (en) 1987-08-07 1992-07-28 Hoechst-Roussel Pharmaceuticals Incorporated Phenylhydrazones as intermediates 1-phenyl-3-(1-piperazenyl)-1H-indazoles
US4999356A (en) 1987-08-07 1991-03-12 Hoechst-Roussel Pharmaceuticals, Inc. 1-phenyl-3-(1-piperazinyl)-1H-indazoles
US4957916A (en) 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5015740A (en) 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US4954503A (en) 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
US5077405A (en) 1989-09-11 1991-12-31 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1-Substituted-4-piperazinyl)-1H-indazoles
JPH03223265A (ja) 1990-01-26 1991-10-02 Dainippon Pharmaceut Co Ltd 環状ジアミン誘導体
US5346968A (en) * 1990-04-21 1994-09-13 Basf Aktiengesellschaft Oligosiloxanes and reinforced thermoplastic and ceramic materials obtainable therewith
FR2663291A1 (fr) * 1990-06-15 1991-12-20 Oreal Procede pour le conditionnement d'un produit dans un flacon, permettant d'assurer une meilleure conservation du produit au cours du stockage et ensemble de conditionnement correspondant.
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
CA2092112A1 (fr) 1992-03-23 1993-09-24 Nobuyoshi Iwata Derives d'indole et d'indazole, mode de preparation et utilisation pour le traitement et la prophylaxie des troubles cerebraux
DE4222705C2 (de) 1992-07-10 1996-04-04 Bartenbach Christian Reflektorelement, Reflektorelementanordnung und Raumbeleuchtungsanordnung
US5494908A (en) 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
ES2187518T3 (es) 1992-11-23 2003-06-16 Aventis Pharma Inc 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados.
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB9305623D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
SE9401802L (sv) * 1994-05-26 1995-11-20 Vattenfall Ab Vägguttag
JPH10503501A (ja) 1994-08-03 1998-03-31 アスタ メディカ アクチエンゲゼルシャフト 抗喘息、抗アレルギー、抗炎症及び免疫修飾作用を有するインドール、インダゾール、ピリドピロール及びピリドピラゾール誘導体
GB9423682D0 (en) 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5998415A (en) 1995-11-02 1999-12-07 Merck Sharp & Dohme Ltd. Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors
GB9523250D0 (en) 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
GB9524356D0 (en) 1995-11-29 1996-01-31 Merck Sharp & Dohme Therapeutic agents
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
JP2002514162A (ja) 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
US6166027A (en) 1996-10-14 2000-12-26 Bayer Aktiengesellschaft Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases
US6015740A (en) * 1997-02-10 2000-01-18 Advanced Micro Devices, Inc. Method of fabricating CMOS devices with ultra-shallow junctions and reduced drain area
US6329412B1 (en) 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
IL135900A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
JPH11279156A (ja) 1998-03-31 1999-10-12 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
DE19821002A1 (de) 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6316440B1 (en) 1998-07-30 2001-11-13 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
JP2000198734A (ja) 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
WO2000076984A2 (fr) 1999-05-21 2000-12-21 Biovitrum Ab Nouveaux composes, et utilisation et preparation de ces derniers
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
US20030176421A1 (en) 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU1918001A (en) 2000-03-17 2001-10-03 Alcon Universal Ltd 5-hydroxy indazole derivatives for treating glaucoma
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
WO2002051837A2 (fr) 2000-12-22 2002-07-04 Wyeth Composes heterocyclylindazole et azaindazole utilises en tant que ligands 5-hydroxytryptamine-6
JP2004531506A (ja) 2001-03-29 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体
US7666867B2 (en) 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US20040034101A1 (en) 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP2003146973A (ja) 2001-11-08 2003-05-21 Dai Ichi Seiyaku Co Ltd うつ病、うつ状態又は不安障害の治療及び／又は予防薬
JP2003146879A (ja) 2001-11-08 2003-05-21 Dai Ichi Seiyaku Co Ltd 精神分裂病治療及び／又は予防薬
WO2003076408A2 (fr) * 2002-03-08 2003-09-18 Abbott Laboratories Derives d'indazole qui sont des activateurs de guanylate cyclase soluble
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2003101994A1 (fr) 2002-05-29 2003-12-11 Abbott Laboratories Composes aromatiques bicycliques condenses utiles dans le traitement de dysfonctionnement sexuel
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
KR20070094747A (ko) * 2004-11-29 2007-09-21 워너-램버트 캄파니 엘엘씨 치료용 피라졸로［３,４-ｂ］피리딘 및 인다졸

Also Published As

Publication number Publication date
PA8653901A1 (es) 2006-09-22
US7423054B2 (en) 2008-09-09
DK1828182T3 (da) 2010-05-10
TNSN07207A1 (fr) 2008-11-21
WO2006056873A2 (fr) 2006-06-01
ES2339794T3 (es) 2010-05-25
AR051970A1 (es) 2007-02-21
US7485636B2 (en) 2009-02-03
JP2008528444A (ja) 2008-07-31
US20080293715A1 (en) 2008-11-27
US20060217376A1 (en) 2006-09-28
AU2005308523B2 (en) 2010-01-07
NO20072972L (no) 2007-08-23
AU2005308523A1 (en) 2006-06-01
KR20070094747A (ko) 2007-09-21
EA012245B1 (ru) 2009-08-28
TWI304063B (en) 2008-12-11
UY29228A1 (es) 2006-06-30
EP1828182A2 (fr) 2007-09-05
CN101111494A (zh) 2008-01-23
CA2588812A1 (fr) 2006-06-01
US20060116376A1 (en) 2006-06-01
IL183485A0 (en) 2007-10-31
ZA200704408B (en) 2009-08-26
GT200500348A (es) 2006-06-13
ATE460415T1 (de) 2010-03-15
DE602005019913D1 (de) 2010-04-22
CR9155A (es) 2007-06-29
NL1030540C2 (nl) 2007-02-26
PE20061062A1 (es) 2006-10-26
TW200631582A (en) 2006-09-16
NL1033403C2 (nl) 2010-01-05
JP4130219B2 (ja) 2008-08-06
NL1033403A1 (nl) 2007-04-20
MX2007006408A (es) 2007-06-22
AP2007004024A0 (en) 2007-06-30
BRPI0518693A2 (pt) 2008-12-02
EP1828182B1 (fr) 2010-03-10
EA200700963A1 (ru) 2008-02-28
WO2006056873A3 (fr) 2006-12-28
NL1030540A1 (nl) 2006-05-30

Similar Documents

Publication Publication Date Title
MA29215B1 (fr) Pyrazolo[3,4-b] pyridines et indazoles therapeutiques
MA31373B1 (fr) Composes amino-heterocycliques
MA27438A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
TN2009000138A1 (fr) Biaryl-ether-urees
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA29693B1 (fr) Derives de xanthine en tant qu'agonistes hm74a selectifs
MA30289B1 (fr) Dérivés d'amines
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA26864A1 (fr) Antagonistes du facteur de liberation de corticotrophine.
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
TW200609231A (en) Mglur1 antagonists as therapeutic agents
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
UA98098C2 (ru) ПРОИЗВОДНЫЕ ПИРИДИНОНА И ИХ ПРИМЕНЕНИЕ КАК ПОЛОЖИТЕЛЬНЫХ АЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
MA24936A1 (fr) Procede d'emulsification
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant